Mumbai, India, September 23, 2024: Qure AI, a healthcare AI driven diagnostics provider specializing in artificial intelligence-driven healthcare solutions, has secured $65 million in its Series D funding round. The new capital injection aims to accelerate the company’s expansion into the U.S. market and enhance its innovative product offerings designed for disease detection.
The funding round also saw participation from renowned entities including Merck & Co.’s Merck Global Health Innovation Fund and Kae Capital, along with existing backers such as Novo Holdings, Health Quad, and TeamFund. Qure.AI plans to utilize these funds not only to strengthen its generative AI models but also to explore potential acquisitions that align with its growth strategy.
Founded in 2016, Qure.AI has rapidly established itself as a leader in AI-powered healthcare solutions. Its technology is currently deployed at over 3,000 imaging sites across more than 90 countries, where it assists healthcare professionals in diagnosing critical diseases such as tuberculosis, lung cancer, and strokes.
The startup claims that its AI algorithms outperform traditional radiologists and physicians in diagnostic accuracy, a testament to the growing capabilities of artificial intelligence in medicine.
The company has garnered regulatory approval for several of its products from both U.S. and European Union authorities, further cementing its commitment to delivering reliable healthcare solutions globally.
Indian AI Startup Qure AI Eyes Global Market with New Funding
“AI is poised to address significant bottlenecks in healthcare delivery,” stated Prashant Warier, co-founder and CEO of Qure AI. “As we integrate our technology into various aspects of healthcare—from drug discovery to patient management and even surgical robotics—we are not just enhancing diagnostics but fundamentally transforming the way healthcare is delivered.”
As the demand for efficient healthcare solutions continues to surge, Qure AI is positioned to play a pivotal role in reshaping the future of medical diagnostics. With its recent funding, the startup is set to advance its mission of harnessing AI to improve health outcomes for patients worldwide.
The latest round of funding was led by prominent investors Lightspeed Venture Partners and 360 ONE Asset Management.
